Replies to post #444321 on Amarin Corp Plc (AMRN)

[lizzy241]

SN5, now I get it. This is why Berg mentions a competitor in the same sentence as V? A game of chess anyone?
Cost for olezarsen is HUGE.

🏷️ 1. List Price (Wholesale Acquisition Cost)
The official U.S. launch price is $595,000 per year.

This is the list price, not what most patients actually pay.

🧾 2. Pharmacy Price (Cash Price Without Insurance)
Drugs.com lists the cash price for a single 80 mg/0.8 mL dose at:

$48,441.55 per injection

Since the therapy is monthly, this aligns with the $595k annual list price.

https://dengyuemed.com/news/tryngolzaolezarsen-approved-for-fcs/?utm_source=copilot.com

[Sagaponack]

I checked chatGPT......and saw this on another board as well.

Look up the market cap of Ionis and Arrowhead. they are in the multibillions

Ionis targets high trigs with its injectable:
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis

A rising tide lifts all boats. Amarin is trying to capitalize off this investor / pharma interest and hoping to pick up scripts in this high trig segment if insurers want a cheaper option that serves the patient population of Ionis and Arrowhead